Natural killer (NK) cells are cytotoxic lymphocytes involved in innate immunity. NK-92, a human NK cell line, may be targeted to tumor-associated antigens in solid malignancies where it exhibits antitumor efficacy, but its clinical utility for treating brain tumors is limited by an inability to cross the blood-brain barrier (BBB). We investigated the potential for focused ultrasound (FUS) to deliver 
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We investigated the feasibility of delivering HER2-specific NK-92 cells to the brain with focused ultrasound (FUS) because in contrast to antibodies and inhibitors, these cells are targeted, possess direct cytolytic activity, and are unaffected by efflux channels (9). Using ultrasound bursts at sub-megahertz frequencies through the intact skull, in combination with timed intravenous (i.v.)
injections of encapsulated perfluorocarbon microbubbles, the permeability of the cerebral vasculature can be non-invasively increased in targeted, focal regions (16, 17) . Cavitation of microbubbles under the influence of ultrasound appears to cause temporary mechanical disruption of endothelial tight junctions, and increased para-and transcellular passage of molecules from the blood into the brain (18, 19) . Contrast-enhanced MRI can be used to identify the regions of contrast extravasation and confirm BBB and BTB disruption (BBBD) (17) . This technique has been shown to increase the penetration of a number of therapeutic agents into the brain in rodent models (20, 21, 22) and has recently been shown to be safe in non-human primates (23) .
We examined whether HER2-specific NK-92-scFv(FRP5)-zeta cells injected intravenously could be delivered to the brain using MRI-guided FUS in a xenograft HER2-expressing breast metastasis model. By transfecting the HER2-specific NK-92 cells with superparamagnetic iron oxide (SPIO) nanoparticles, we were able to track their accumulation at the tumor site. Furthermore, we quantified the density of effector-to-tumor cells in order to confirm that the number was sufficient to successfully treat a tumor, and assessed the cytolytic function of HER2-specific NK-92 cells following exposure to ultrasound in vivo. Author Manuscript Published OnlineFirst on January 9, 2013; DOI: 10.1158/0008-5472. CAN-12-2609 Cell Lines and Culture Human HER2-expressing MDA-MB-231 breast tumor cells were cells were isolated from brain metastases, secondary to a primary tumor implanted in a mouse mammary fat pad, and transfected to express HER2 as previously reported (24) . MDA-MB-231-HER2 cells were maintained in RPMI 1640 media supplemented with 10% fetal bovine serum (Wisent, St. Bruno, QC Canada). For implantation, cells were collected, centrifuged and resuspended in Hanks' balanced salt solution (HBSS; Wisent) at a concentration of 10 3 cells/μl. HER2 expression was confirmed using immunocytochemistry. MDA-MB-231-HER2 cells were plated on 8 well chamber slides (Nunc, Roskilde, Denmark) for 24 hrs and then fixed with 4% paraformaldehyde for 10 min at room temperature. Cells were treated with blocking solution containing 1% donkey serum for 1 hr followed by incubation with primary rabbit anti-HER2 (Thermo Fisher Scientific, Nepean, ON Canada) overnight. Slides were washed and incubated with donkey anti-mouse Cy3 for 1 hr, and coverslipped. Fluorescent images were captured with a Zeiss Axiovert microscope.
Materials and Methods
The human cell line, NK-92 (ATCC, Manassas, VA), was virally transduced to stably express a chimeric antigen receptor specific to HER2 (10) . The antigen receptor expression was confirmed by fluorescence activated cell sorter (FACS) analysis (10) . HER2-specific NK-92-scFv(FRP5)-zeta cells were maintained in X-VIVO 10 medium (Lonza, Basel, Switzerland) supplemented with 5% heatinactivated human serum (Cedarlane, Burlington, ON Canada), 0.6 mg/ml G418 (Wisent, St. Bruno,
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Burlington, ON Canada) for 30 min and subsequently added to 10 6 NK-92 cells in normal media for 24 hrs at 37° (11) . Cells were collected, centrifuged and resuspended in sterile, physiological saline at a concentration of 10 7 cells/ml for injection in vivo. Transfection efficiency was estimated using light microscopy to identify SPIO nanoparticles within the cell cytoplasm.
Tumor Implantation
All procedures were approved by the Sunnybrook Research Institute Animal Care and Use Committee and conformed to the guidelines set out by the Canadian Council on Animal Care. General anesthesia was induced and maintained with isofluorane in 250-300 g male athymic nude rats (Charles River, Sherbrooke, QC Canada). A burrhole was fashioned in the skull and cells were implanted in the left frontal striatum with a Hamiton syringe guided by stereotactic frame, at a depth of 4 mm from the cortical surface. MDA-MB-231-HER2 cells were combined with a 1% agar solution at 37°C to a final density of 10 3 cells/µL, and 10 µL were injected (25) . Animals underwent serial MRI imaging and the tumors treated once they had reached 1.5-2 mm in size.
MRI-guided Focused Ultrasound
In preparation for BBBD, animals were anesthetized with ketamine (90 mg/kg) and xylazine Figure   1 ) by 12.5 mm in the beam direction (z direction in Figure 1 ). The tumors were therefore completely encompassed by the focus.
Targeting and registration images were acquired with a 1.5T clinical MRI scanner (Signa, GE Healthcare, Milwaukee, WI). All animals underwent baseline T2-(FOV 6 cm, 128x128 matrix, slice thickness 1 mm, NEX 2, ETL 4, TR 2000 ms, TE 75ms) and T1-weighted (FOV 6 cm, 128x128 matrix, slice thickness 1 mm, NEX 6, ETL 4, TR 500, TE ~10ms) MR imaging, including a contrast enhanced (0.2 ml/kg; Omniscan, GE Healthcare, Milwaukee, WI) sequence, to identify the tumor. Following MRI and ultrasound co-registration, the computer-controlled 3-axis positioning system allowed the focal spot of the transducer to be positioned at any location within the brain. BBBD was performed (10 ms pulses, 1 Hz pulse repetition frequency, 120 s total duration) using a controller to modulate the acoustic power (0.33 MPa average estimated peak rarefaction pressure in the brain; range 0.32-0.35 MPa) (27) . The estimated in-situ pressure was determined assuming 73% transmission through the rat skull (28) 
Cytotoxicity Assay
Cytotoxicity assays were performed to determine the extent of MDA-MB-231-HER2 cell death achieved using differing effector-to-tumor cell ratios. 10 
Statistical Analysis
GraphPad Prism 5 (GraphPad Software, San Diego, CA) was used for statistical analysis.
Student's t test was used to compare the means ± SEM of two groups and the means ± SEM of three or more groups were compared with one-way ANOVA and Tukey's post-test. Statistical significance was noted if p < 0.05. 
Results
Prior to implantation, HER2 expression in MDA-MB-231-HER2 cells was determined to be 80% using immunohistochemistry (IHC). CD45 expression by HER2-specific NK-92 cells was found to be 100% using IHC. The average transfection efficiency of HER2-specific NK-92 cells with SPIO nanoparticle was 80% and did not affect their cytolytic function.
Representative pre-and post-treatment contrast-enhanced T1-weighted MR images are shown in Figure 3A and 3B. The degree of contrast enhancement following BBBD was relatively uniform and was double that of the tumor region prior to treatment (34 ± 10% versus 17 ± 8%, p=0.01). All animals tolerated the cell injection and BBBD without complication, and recovered from general anesthesia to their pre-treatment condition. No abnormal behavior was noted in the 16 hour interval between treatment and sacrifice. Post-treatment 7T MR imaging detected HER2-specific NK-92 cells at the tumor site in group 3 by a -17 ± 4% change in the signal intensity versus a 14 ± 7% change in group 1 (p < 0.001). Representative pre-and post-treatment T2*-weighted sequences are shown in Figures 3A and 3B. The differences between other groups were not found to be statistically significant (p > 0.05, Figure 4C ).
Following animal sacrifice, H&E stained sections were examined for tissue injury. One FUStreated animal had a small region of erythrocyte extravasation adjacent the tumor ( Figure 3C ). HER2-specific NK-92 cells were counted using both CD45 expression and the presence of intracellular iron on Prussian blue stained sections, and expressed as number of effector cells per 100 tumour cells.
Without BBBD, a very small number of HER2-specific NK-92 cells localized to the tumor (group 1, 0.09 ± 0.11, Figure 5 ), and almost equally few reached the tumor when BBBD was done prior to the injection of cells into the circulation (group 2, 0.21 ± 0.15, Figure 5 ). In contrast, the ratio of HER2- 
compared to injection afterward (group 3, 0.95 ± 0.23, Figure 5 ). The number of effector cells accumulating in the sonicated tumors in group 3 corresponds to approximately 0.34% of the total number of cells injected. This increase was statistically significant when compared to the former two groups (p < 0.01, Figure 5B ). There was no statistical difference between group 1 and 2. More dense accumulations of cells were observed around arterioles and venules in group 3, with an effector:tumor ratio significantly greater than the volume-averaged value ( Figure 6A and 6C) . Furthermore, cells were identified outside of the tumor boundary in a number of sections in group 3 but not counted in the analysis; theoretically these cells could migrate to the tumor and contribute to a higher effector to tumor cell ratio.
We also examined whether HER2-specific NK-92 cells circulating prior to BBBD would be nitric oxide (NO) from endothelial cells in vitro (33, 34) , as well as increases the expression of caveolin-1 in vivo (35) , and thus it is conceivable that BBBD could affect the expression of proteins involved in leukocyte adhesion. Furthermore, the interaction of ultrasound and microbubbles with the HER2-targeted NK-92 cells may play a role. Microbubbles undergoing stable cavitation are known to generate shear stresses (36, 37, 38) , and increased fluid shear stresses have a number of in vitro effects on activated leukocytes including increased adhesion (39, 40) , deformability (41) , motility (42) , and transmigration (42, 43) . Although speculatory, it is possible that circulating HER2-specific NK-92 cells are more likely to adhere to endothelium and extravasate following exposure to fluid shear stresses generated by microbubbles at the ultrasound focus. These in vitro studies typically required fluid shear stresses in the setting of an activated endothelium, and therefore from the group 2 results (where the endothelium was exposed to FUS but the HER2-specific NK-92 cells were not) the effect of BBBD on the endothelium alone is one that at least partially promotes leukocyte extravasation, either by disrupting endothelial tight junctions or through some unknown mechanism. Finally, there may be direct mechanical effects of the oscillating microbubbles on the effector cells that have yet to be elucidated.
In addition to the increased accumulation of HER2-specific NK-92 cells in group 3 tumors, dense accumulations of HER2-specific NK-92 cells around arterioles and venules in group 3 ( Figure   6A and 6C). Larger vessels may have permitted greater microbubble activity (decreased bubble damping compared to capillary sized vessels, or a bubble population with a mean size closer to the resonant frequency used), or possibly was able to support larger inter-endothelial openings. Along capillaries, the effector cells were seen to line the adluminal surface, even in the absence of nearby tumor cells (Figure 6B and 6D) . We did not see any of these features in group 1 or 2 animals. Of particular note in both ultrasound-treated groups is the absence of erythrocytes amongst extravasated HER2-specific NK-92 cells (there was a small region of erythrocyte extravasation adjacent the tumor on April 11, 2017. © 2013 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from absent effector cells). It is believed this is in keeping with the postulated mechanism for the increased leukocyte extravasation with BBBD. The inter-endothelial openings, only studied post-BBBD, have been shown to be on the order of tens to hundreds of nanometers, and thus much smaller than the diameter of an erythrocyte (18, 44) . Erythrocytes are typically dispersed with little adherence to endothelial cells in the face of fluid shear stresses (45) , whereas the reverse is true for leukocytes (39) (40) (41) (42) (43) .
Of significant concern was whether HER2-specific NK-92 cells circulating at the time of the BBBD would maintain their cytolytic function. Figure 6A and 6C show a large group of extravascular HER2-specific NK-92 cells surrounding an extra-tumoral venule. In such a vessel (outside the tumor but within the ultrasound focus), the direction of extravasation should be random, but the preferential clustering of cells toward the tumor suggests preserved bioactivity of the cells. Furthermore, perforin and granzyme B IHC provided evidence that these mediators of apoptosis were being released into the intercellular space, and a number of apoptotic cells were identified in close association with HER2-specific NK-92 cells ( Figure 7A and 7B) . In addition to preserved biological function, we estimated that the effector-to-target cell ratios realized would be sufficient to result in efficient tumor cell lysis ( Figure 7C ). Because the SPIO nanoparticle transfection efficiency was less than 100%, the calculated densities likely underestimate the actual number of HER2-specific NK-92 cells reaching the tumors.
We have demonstrated for the first time the feasibility of using targeted immune cells combined line has already been used in early clinical trials (29, 30) and with the expanding clinical testing of FUS, and also the recent demonstration of the safety and repeatability of BBBD in rhesus macaques (23) , this treatment has the potential to benefit patients with brain metastasis in the foreseeable future. 
Figure Legends
